Pieris Pharmaceuticals Debt 2024

Pieris Pharmaceuticals Aktienanalyse

What does Pieris Pharmaceuticals do?

Pieris Pharmaceuticals Inc is a biotechnology company that focuses on the development of therapeutic antibodies. The company was founded in 2001 in Freising, Germany, and has since relocated its headquarters to Boston, USA. The company's history traces back to the research group of Professor Arne Skerra at the Technical University of Munich, which specialized in the development of new protein engineering technologies. Together with another biotech company, Swiss CYTHERIS SA, they eventually founded Pieris Pharmaceuticals Inc. The company received $10 million in funding in 2004 from international investors, including some German funds. Since then, the company has had several successful IPOs and has become one of the leading biotech companies in antibody research. The business model of Pieris Pharmaceuticals is based on the development and commercialization of antibodies that can be used as therapeutics for various diseases. The company combines its own research and development efforts with partnerships with other companies and organizations. The company's divisions include the development of antibodies for the treatment of cancer and immune-related diseases, the development of antibodies to combat infectious diseases, and the development of novel antibody platforms to generate broad antibody spectra. One of Pieris Pharmaceuticals' most successful products is the antibody PRS-343, which was developed as a therapeutic for HER2-positive breast cancer. A study showed that PRS-343, in combination with the chemotherapy drug Herceptin, has a higher efficacy than Herceptin alone. Another promising project is the development of an antibody for the treatment of tumors in the gastrointestinal tract. The substance PRS-276 is able to selectively attack and kill these cells due to its high affinity to the tumor antigen Claudin18.2. Overall, Pieris Pharmaceuticals Inc has launched numerous successful projects in recent years and has expanded its competitive position in the biotech industry. The company aims to closely collaborate with partners from the pharmaceutical industry to accelerate and optimize the development and commercialization of its products. Pieris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Pieris Pharmaceuticals's Debt Structure

Pieris Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Pieris Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Pieris Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Pieris Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Pieris Pharmaceuticals stock

What is the debt of Pieris Pharmaceuticals this year?

Pieris Pharmaceuticals has a debt level of -17.4 USD this year.

What was the debt of Pieris Pharmaceuticals compared to the previous year?

The debt of Pieris Pharmaceuticals has increased by -54.97% compared to the previous year dropped.

What are the consequences of high debt for investors in Pieris Pharmaceuticals?

High debt can pose a risk for investors of Pieris Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Pieris Pharmaceuticals?

Low debt means that Pieris Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Pieris Pharmaceuticals affect the company?

An increase in debt of Pieris Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Pieris Pharmaceuticals affect the company?

A reduction in debt of Pieris Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Pieris Pharmaceuticals?

Some factors that can influence the debt of Pieris Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Pieris Pharmaceuticals so important for investors?

The debts of Pieris Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Pieris Pharmaceuticals take to change the debt?

To change the debt, Pieris Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Pieris Pharmaceuticals pay?

Over the past 12 months, Pieris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pieris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Pieris Pharmaceuticals?

The current dividend yield of Pieris Pharmaceuticals is .

When does Pieris Pharmaceuticals pay dividends?

Pieris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pieris Pharmaceuticals?

Pieris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Pieris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pieris Pharmaceuticals located?

Pieris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pieris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pieris Pharmaceuticals from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Pieris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Pieris Pharmaceuticals in the year 2023?

In the year 2023, Pieris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Pieris Pharmaceuticals pay out the dividend?

The dividends of Pieris Pharmaceuticals are distributed in USD.